Prostate Cancer Clinical Trial
Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients With Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study
|Source||Profound Medical Inc.|
|Start date||September 21, 2016|
|Completion date||September 2022|
A prospective, multi-center, single-arm study, planned in 110 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate tissue of patients with localized, organ-confined prostate cancer.
Profound Medical Inc. has developed a novel technology called the MRI-guided transurethral
ultrasound therapy system (TULSA-PRO). The technology is developed for patients with organ
confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation
of prostate tissue.
The treatment is conducted within a MRI suite, which enables real-time temperature images of the heated region to be acquired as the ultrasonic treatment is delivered. Using MRI thermometry during treatment, dynamic temperature feedback control over the intensity of the ultrasound beams and rotation of the Ultrasound Applicator can shape the pattern of thermal coagulation accurately and precisely in the prostate gland.
It provides advantages of a non-invasive procedure with short treatment times.
|Recruiting||NCT03177759 - Living With Prostate Cancer (LPC)||N/A|
|Completed||NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data||N/A|
|Not yet recruiting||NCT03160365 - Innovative Planning and Guidance System for Prostate Focal Brachytherapy||N/A|
|Active, not recruiting||NCT02124668 - A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy||Phase 2|
|Completed||NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis||N/A|
|Active, not recruiting||NCT00779168 - White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy||Phase 1|
|Recruiting||NCT01990196 - Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer||Phase 2|
|Not yet recruiting||NCT03157947 - Culturally Tailored Decision Aid for Hispanic Patients Diagnosed With Prostate Cancer||N/A|
|Recruiting||NCT02918357 - Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence||Phase 2/Phase 3|
|Recruiting||NCT02886598 - Safety and Efficacy of Firmagon® (Degarelix) for Injection||N/A|
|Recruiting||NCT02911922 - Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer||N/A|
|Recruiting||NCT02919111 - Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients||Phase 2/Phase 3|
|Recruiting||NCT02917161 - Prostatic Artery Embolization Before Radical Prostatectomy in Prostate Cancer: A Proof-of-concept Study||N/A|
|Recruiting||NCT02766686 - Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons||N/A|
|Recruiting||NCT02747342 - A Phase 1 Trial of SHR3680 in Prostate Cancer as Monotherapy||Phase 1|
|Recruiting||NCT02916537 - A Phase 1 Trial for Safety and Imaging Evaluation of CTT1057, a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA)||Phase 1|
|Recruiting||NCT02906241 - PACCT: Partnering Around Cancer Clinical Trials||N/A|
|Recruiting||NCT02543255 - Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)||Phase 2|
|Enrolling by invitation||NCT02840552 - The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate Cancer||Phase 3|
|Not yet recruiting||NCT02816840 - PET-CT/MRI in the Radiotherapy for Prostate Cancer||Phase 1/Phase 2|